Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 3
Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Panelists discuss how patient selection for quadruplet therapy in transplant-ineligible/deferred NDMM requires careful consideration of multiple factors, including fitness level and comorbidities, while highlighting daratumumab-VRd’s potential advantages such as subcutaneous administration and demonstrated efficacy in the CEPHEUS trial despite increased complexity and cost considerations.
Video content above is prompted by the following:
- How do you determine which patients are best suited for quadruplet therapy?
- What outcomes and factors are critical to consider?
- MRD negativity? Depth of response? Safety? Relapse? Other?
- Share perspectives on how the Dara-VRd regimen from CEPHEUS could impact the treatment landscape for TIE or deferred NDMM.
- What advantages (ie, SC administration) does the regimen provide?
- What other benefits or challenges should be considered?
Related Content:
